| Name | Market Cap | Current Price | P/E Ratio | Revenue Growth 1Y | Net Margin | ROE | FCF Yield | Debt/Equity |
|---|---|---|---|---|---|---|---|---|
| ANVSAnnovis Bio, Inc. | 84.81M | 3.20 | -0.00 | -189.15% | ||||
| CLNNClene Inc. | 60.19M | 5.11 | -0.90 | -47.71% | -142.5% | -17.38% | ||
| ABOSAcumen Pharmaceuticals, Inc. | 112.67M | 1.86 | -1.09 | -143.12% | 0.16 | |||
| BHVNBiohaven Ltd. | 1.58B | 11.92 | -1.28 | -198.83% | 0.09 | |||
| IKTInhibikase Therapeutics, Inc. | 200.09M | 1.65 | -1.42 | -100% | -65.37% | 0.00 | ||
| ALECAlector, Inc. | 198.66M | 1.82 | -1.48 | 3.6% | -156.03% | -186.68% | 0.34 | |
| CGTXCognition Therapeutics, Inc. | 121.82M | 1.38 | -1.62 | -76.61% | 0.04 | |||
| ATHEAlterity Therapeutics Limited | 60M | 3.31 | -2.90 | 35.32% | -330.63% | -73.75% | 0.00 |
| Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 1.67M | 1.4M | 1.4M | 1.73M | 54K | 3.04M | 500K | 3.15M | 56K |
| Revenue Growth % | - | -0.16% | -0.01% | 0.24% | -0.97% | 55.28% | -0.84% | 5.31% | -0.98% |
| Cost of Goods Sold | 911K | 685K | 841K | 998.5K | 1.28M | 0 | 0 | 90K | 194K |
| COGS % of Revenue | 0.55% | 0.49% | 0.6% | 0.58% | 23.72% | - | - | 0.03% | 3.46% |
| Gross Profit | 755K | 719K | 555K | 729.5K | -1.23M | 3.04M | 500K | 3.06M | -138K |
| Gross Margin % | 0.45% | 0.51% | 0.4% | 0.42% | -22.72% | 1% | 1% | 0.97% | -2.46% |
| Gross Profit Growth % | - | -0.05% | -0.23% | 0.31% | -2.68% | 3.48% | -0.84% | 5.13% | -1.05% |
| Operating Expenses | 13.49M | 9.14M | 11M | 13.29M | 9.18M | 4.67M | 2.77M | 6.19M | 16.91M |
| OpEx % of Revenue | 8.1% | 6.51% | 7.88% | 7.69% | 170% | 1.54% | 5.54% | 1.96% | 301.96% |
| Selling, General & Admin | 5.62M | 3.87M | 5.65M | 7.94M | 5.6M | 1.3M | 1.29M | 3.89M | 9.43M |
| SG&A % of Revenue | 3.37% | 2.76% | 4.05% | 4.6% | 103.67% | 0.43% | 2.58% | 1.24% | 168.39% |
| Research & Development | 7.87M | 5.27M | 5.35M | 5.35M | 3.58M | 3.8M | 1.57M | 2.39M | 7.48M |
| R&D % of Revenue | 4.73% | 3.75% | 3.83% | 3.09% | 66.33% | 1.25% | 3.15% | 0.76% | 133.57% |
| Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | -425.57K | -91.5K | -90K | 0 |
| Operating Income | -12.74M | -8.42M | -10.45M | -12.56M | -10.41M | -1.63M | -2.27M | -3.13M | -17.05M |
| Operating Margin % | -7.65% | -6% | -7.48% | -7.27% | -192.72% | -0.54% | -4.54% | -0.99% | -304.43% |
| Operating Income Growth % | - | 0.34% | -0.24% | -0.2% | 0.17% | 0.84% | -0.39% | -0.38% | -4.45% |
| EBITDA | -11.89M | -7.74M | -9.91M | -11.61M | -9.15M | -1.6M | -2.21M | -3.04M | -16.85M |
| EBITDA Margin % | -7.14% | -5.51% | -7.1% | -6.72% | -169.48% | -0.53% | -4.42% | -0.96% | -300.96% |
| EBITDA Growth % | - | 0.35% | -0.28% | -0.17% | 0.21% | 0.83% | -0.38% | -0.38% | -4.55% |
| D&A (Non-Cash Add-back) | 845K | 682K | 535K | 951K | 1.25M | 33.37K | 61.27K | 90K | 194K |
| EBIT | -17.33M | -6.63M | -7.73M | -12.24M | -9.99M | -1.26M | -2.67M | 5.83M | -10.68M |
| Net Interest Income | 0 | 0 | 0 | 29K | -404K | 7.76K | -14.12K | -558K | -526K |
| Interest Income | 0 | 0 | 116K | 29K | 0 | 10.86K | 1.76K | 0 | 0 |
| Interest Expense | 25K | 12K | 0 | 0 | 404K | 3.09K | 15.88K | 558K | 526K |
| Other Income/Expense | -4.62M | 1.78M | 2.71M | 323K | 8K | 366.81K | -411.74K | 8.4M | 5.84M |
| Pretax Income | -17.36M | -6.64M | -7.73M | -12.24M | -10.4M | -1.26M | -2.68M | 5.27M | -11.21M |
| Pretax Margin % | -10.42% | -4.73% | -5.54% | -7.08% | -192.57% | -0.42% | -5.36% | 1.67% | -200.13% |
| Income Tax | 0 | -57K | 0 | 148K | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0.89% | 0.99% | 0.97% | 0.99% | 1.04% | 1% | 1% | 1% | 0.99% |
| Net Income | -15.49M | -6.58M | -7.5M | -12.15M | -10.87M | -1.26M | -2.68M | 5.27M | -11.14M |
| Net Margin % | -9.3% | -4.69% | -5.37% | -7.03% | -201.2% | -0.42% | -5.36% | 1.67% | -198.95% |
| Net Income Growth % | - | 0.58% | -0.14% | -0.62% | 0.11% | 0.88% | -1.12% | 2.96% | -3.11% |
| Net Income (Continuing) | -17.36M | -6.64M | -7.73M | -12.38M | -10.4M | -1.26M | -2.68M | 5.27M | -11.21M |
| Discontinued Operations | 0 | 0 | 0 | 0 | -471K | 0 | 0 | 0 | 0 |
| Minority Interest | 1.04M | 1.04M | 784K | 399K | -280K | -43K | -103K | 0 | -133K |
| EPS (Diluted) | -15.21 | -6.46 | -7.56 | -11.47 | -10.14 | -8.05 | -2.49 | 0.63 | -1.51 |
| EPS Growth % | - | 0.58% | -0.17% | -0.52% | 0.12% | 0.21% | 0.69% | 1.25% | -3.4% |
| EPS (Basic) | -15.21 | -6.46 | -7.56 | -11.47 | -10.14 | -8.05 | -2.49 | 0.63 | -1.51 |
| Diluted Shares Outstanding | 1.02M | 1.02M | 992.72K | 1.06M | 1.07M | 1.08M | 1.08M | 8.41M | 7.36M |
| Basic Shares Outstanding | 1.02M | 1.02M | 992.72K | 1.06M | 1.07M | 1.08M | 1.08M | 8.41M | 7.36M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - |
| Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 688K | 7.59M | 7.85M | 4.05M | 2.28M | 2.23M | 2.45M | 7.62M | 5.68M |
| Cash & Short-Term Investments | 259K | 7.38M | 6.71M | 2.35M | 527K | 584K | 645K | 7.62M | 3.67M |
| Cash Only | 259K | 7.38M | 6.71M | 2.35M | 527K | 584K | 645K | 7.62M | 3.67M |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 308K | 107K | 131K | 363K | 326K | 25K | 4K | 0 | 0 |
| Days Sales Outstanding | 67.48 | 27.82 | 34.25 | 76.68 | 2.2K | 3 | 2.92 | - | - |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - | - |
| Other Current Assets | 121K | 111K | 1.01M | 1.34M | 1.43M | 1.63M | 1.8M | 0 | 77K |
| Total Non-Current Assets | 2.54M | 2.04M | 2.82M | 3.39M | 1.64M | 920K | 788K | 1.35M | 1.05M |
| Property, Plant & Equipment | 195K | 129K | 90K | 1.13M | 0 | 0 | 0 | 1.35M | 1.05M |
| Fixed Asset Turnover | 8.54x | 10.88x | 15.51x | 1.53x | - | - | - | 2.34x | 0.05x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 2.15M | 1.59M | 0 | 738K | 0 | 0 |
| Long-Term Investments | 0 | 0 | 0 | 0 | 50K | 50K | 50K | 0 | 0 |
| Other Non-Current Assets | 2.34M | 1.91M | 2.73M | 111K | 0 | 870K | 0 | 0 | 0 |
| Total Assets | 3.22M | 9.63M | 10.67M | 7.44M | 3.92M | 3.15M | 3.24M | 8.97M | 6.72M |
| Asset Turnover | 0.52x | 0.15x | 0.13x | 0.23x | 0.01x | 0.96x | 0.15x | 0.35x | 0.01x |
| Asset Growth % | - | 1.99% | 0.11% | -0.3% | -0.47% | -0.2% | 0.03% | 1.77% | -0.25% |
| Total Current Liabilities | 25.6M | 1.31M | 2.44M | 3.3M | 5.36M | 8.97M | 10.08M | 1.41M | 2.37M |
| Accounts Payable | 261K | 75K | 150K | 420K | 761K | 193K | 568K | 580K | 744K |
| Days Payables Outstanding | 104.57 | 39.96 | 65.1 | 153.53 | 216.83 | - | - | 2.35K | 1.4K |
| Short-Term Debt | 0 | 0 | 0 | 428K | 2.4M | 7.14M | 7.65M | 0 | 0 |
| Deferred Revenue (Current) | 264K | 180K | 317K | 283K | 275K | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 25.07M | 1.06M | 1.97M | 2.17M | 1.93M | 1.63M | 1.67M | 250K | 1.06M |
| Current Ratio | 0.03x | 5.79x | 3.22x | 1.23x | 0.43x | 0.25x | 0.24x | 5.39x | 2.40x |
| Quick Ratio | 0.03x | 5.79x | 3.22x | 1.23x | 0.43x | 0.25x | 0.24x | 5.39x | 2.40x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 0 | 0 | 0 | 1.53M | 3.96M | 6.06M | 10.48M | 39.85M | 3.85M |
| Long-Term Debt | 0 | 0 | 0 | 1.53M | 3.9M | 6.06M | 10.48M | 2.98M | 0 |
| Capital Lease Obligations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 462K | 268K |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 36.4M | 3.58M |
| Total Liabilities | 25.6M | 1.31M | 2.44M | 4.83M | 9.32M | 15.03M | 20.56M | 41.26M | 6.22M |
| Total Debt | 0 | 0 | 0 | 1.96M | 6.3M | 13.2M | 18.12M | 3.44M | 268K |
| Net Debt | -259K | -7.38M | -6.71M | -396K | 5.77M | 12.62M | 17.48M | -4.17M | -3.4M |
| Debt / Equity | - | - | - | 0.75x | - | - | - | - | 0.53x |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | - |
| Interest Coverage | -509.56x | -701.42x | - | - | -25.76x | -527.31x | -142.99x | -5.61x | -32.41x |
| Total Equity | -22.38M | 8.32M | 8.23M | 2.62M | -5.4M | -11.88M | -17.32M | -32.29M | 508K |
| Equity Growth % | - | 1.37% | -0.01% | -0.68% | -3.06% | -1.2% | -0.46% | -0.87% | 1.02% |
| Book Value per Share | -21.96 | 8.17 | 8.29 | 2.47 | -5.04 | -11.02 | -16.05 | -3.84 | 0.07 |
| Total Shareholders' Equity | -23.42M | 7.28M | 7.45M | 2.22M | -5.12M | -11.83M | -17.21M | -32.29M | 641K |
| Common Stock | 3K | 3K | 4K | 4K | 4K | 4K | 4K | 0 | 1K |
| Retained Earnings | -59.97M | -66.55M | -74.05M | -86.21M | -97.07M | -105.75M | -116.21M | -33.18M | -44.32M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 58K | 68K | -2K | 69K | 143K | 0 | 0 | 0 | 0 |
| Minority Interest | 1.04M | 1.04M | 784K | 399K | -280K | -43K | -103K | 0 | -133K |
| Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -8.43M | -6.29M | -8M | -10.16M | -7.82M | -2.25M | -2.08M | -2.48M | -17.14M |
| Operating CF Margin % | -5.06% | -4.48% | -5.73% | -5.88% | -144.76% | -0.74% | -4.15% | -0.79% | -306.02% |
| Operating CF Growth % | - | 0.25% | -0.27% | -0.27% | 0.23% | 0.71% | 0.08% | -0.19% | -5.92% |
| Net Income | -15.49M | -6.58M | -7.5M | -12.15M | -10.39M | -1.26M | -2.68M | 5.27M | -11.21M |
| Depreciation & Amortization | 845K | 682K | 535K | 951K | 1.25M | 33.37K | 61.27K | 90K | 194K |
| Stock-Based Compensation | 0 | 0 | 0 | 0 | 0 | 82.94K | 7.11K | 25K | 2.6M |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 5.42M | -388K | -793K | 1.45M | 1.58M | -347.59K | 550.04K | -7.94M | -5.4M |
| Working Capital Changes | 1.31M | 776K | 211K | -410K | -260K | -754.79K | -11.94K | 81K | -3.32M |
| Change in Receivables | -57K | 322K | -24K | -232K | -30K | 1.27M | 1.11K | 0 | 65K |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 1.24M | 267K | 648K | 169K | 382K | -367.29K | -2.13K | 393K | -1.66M |
| Cash from Investing | -28K | 5K | 1.33M | -361K | -20K | 823.32K | 980.94K | -504K | -22K |
| Capital Expenditures | -23K | -1K | -1.89M | -641K | -20K | -108.43K | -9.68K | -504K | -22K |
| CapEx % of Revenue | 0.01% | 0% | 1.36% | 0.37% | 0.37% | 0.04% | 0.02% | 0.16% | 0.39% |
| Acquisitions | - | - | - | - | - | - | - | - | - |
| Investments | - | - | - | - | - | - | - | - | - |
| Other Investing | -5K | 6K | 5K | -74K | 0 | 0 | 0 | 0 | 0 |
| Cash from Financing | 7.25M | 13.28M | 6M | 6.26M | 5.96M | 1.08M | 1.31M | 10.07M | 13.21M |
| Debt Issued (Net) | - | - | - | - | - | - | - | - | - |
| Equity Issued (Net) | - | - | - | - | - | - | - | - | - |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | - | - | - | - | - | - | - | - | - |
| Other Financing | 4.81M | 1.3M | 0 | 0 | 0 | 1M | 0 | 0 | 5.34M |
| Net Change in Cash | - | - | - | - | - | - | - | - | - |
| Free Cash Flow | -8.45M | -6.29M | -9.89M | -10.8M | -7.84M | -2.36M | -2.09M | -2.98M | -17.16M |
| FCF Margin % | -5.07% | -4.48% | -7.08% | -6.25% | -145.13% | -0.78% | -4.17% | -0.95% | -306.41% |
| FCF Growth % | - | 0.26% | -0.57% | -0.09% | 0.27% | 0.7% | 0.12% | -0.43% | -4.76% |
| FCF per Share | -8.29 | -6.17 | -9.96 | -10.19 | -7.32 | -2.19 | -1.93 | -0.35 | -2.33 |
| FCF Conversion (FCF/Net Income) | 0.54x | 0.96x | 1.07x | 0.84x | 0.72x | 1.78x | 0.77x | -0.47x | 1.54x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 3.09K | 15.88K | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | - | -79.1% | -90.66% | -224.08% | - | - | - | - | -2193.11% |
| Return on Invested Capital (ROIC) | - | -668.72% | -634.83% | -503.03% | -601.79% | -219.29% | -375.47% | - | - |
| Gross Margin | 45.32% | 51.21% | 39.76% | 42.22% | -2272.22% | 100% | 100% | 97.15% | -246.43% |
| Net Margin | -929.89% | -468.66% | -537.39% | -703.36% | -20120.37% | -41.61% | -536.42% | 167.11% | -19894.64% |
| Debt / Equity | - | - | - | 0.75x | - | - | - | - | 0.53x |
| Interest Coverage | -509.56x | -701.42x | - | - | -25.76x | -527.31x | -142.99x | -5.61x | -32.41x |
| FCF Conversion | 0.54x | 0.96x | 1.07x | 0.84x | 0.72x | 1.78x | 0.77x | -0.47x | 1.54x |
| Revenue Growth | - | -15.73% | -0.57% | 23.78% | -96.88% | 5528.12% | -83.55% | 530.6% | -98.22% |
Serina Therapeutics, Inc. (SER) reported $0.1M in revenue for fiscal year 2024. This represents a 93% decrease from $1.7M in 2016.
Serina Therapeutics, Inc. (SER) saw revenue decline by 98.2% over the past year.
Serina Therapeutics, Inc. (SER) reported a net loss of $18.6M for fiscal year 2024.
Serina Therapeutics, Inc. (SER) has a return on equity (ROE) of -2193.1%. Negative ROE indicates the company is unprofitable.
Serina Therapeutics, Inc. (SER) had negative free cash flow of $16.5M in fiscal year 2024, likely due to heavy capital investments.